Alpha 2.0
Login Register
» Authors » Noppadol Siritanaratkul

Noppadol Siritanaratkul

Explore the profile of Noppadol Siritanaratkul including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 1302
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
Vip Viprakasit
Suporn Chuncharunee
Suthat Fucharoen
Zeynep Karakas
Antonis Kattamis
Ali T Taher
Ruchaneekorn W Kalpravidh
Suneerat Hatairaktham
Narumol Panichkul
Jian Hou
Published In
Br J Haematol
Am J Hematol
Ann Hematol
Blood Cells Mol Dis
Lancet Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Whole exome sequencing and rare variant association study to identify genetic modifiers, mutations, and a novel double mutation in Thai patients with hemoglobin E/beta-thalassemia
Hantaweepant C, Suktitipat B, Pithukpakorn M, Chinthammitr Y, Limwongse C, Tansiri N, et al.
Hematology . 2023 Mar; 28(1):2187155. PMID: 36939018
Objectives: Clinical manifestations of patients with Hemoglobin E/beta-thalassemia vary from mild to severe phenotypes despite exhibiting the same genotype. Studies have partially identified genetic modifiers. We aimed to study the...
2.
An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results
Lai Y, Cappellini M, Aydinok Y, Porter J, Karakas Z, Viprakasit V, et al.
Am J Hematol . 2022 May; 97(8):E281-E284. PMID: 35560253
No abstract available.
3.
An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines
Ekwattanakit S, Hantaweepant C, Khuhapinant A, Siritanaratkul N, Viprakasit V
Sci Rep . 2021 Jun; 11(1):13283. PMID: 34168246
Based on Thalassemia International Federation clinical practice guidelines (CPG) for non-transfusion dependent and transfusion dependent thalassemia, several measures should be routinely implemented such as monitoring and surveillance of thalassemia related...
4.
Exploring health-related quality of life among non-Hodgkin's lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand
Lekdamrongkul P, Pongthavornkamol K, Molassiotis A, Sriyuktasuth A, Siritanaratkul N, Chansatitporn N
Support Care Cancer . 2021 Apr; 29(11):6511-6522. PMID: 33909148
Purposes: To investigate health-related quality of life (HR-QoL) and its influencing factors among non-Hodgkin's lymphoma (NHL) survivors after completion of primary treatment. Methods: A cross-sectional study with 312 NHL survivors...
5.
Curcuminoids supplementation ameliorates iron overload, oxidative stress, hypercoagulability, and inflammation in non-transfusion-dependent β-thalassemia/Hb E patients
Hatairaktham S, Masaratana P, Hantaweepant C, Srisawat C, Sirivatanauksorn V, Siritanaratkul N, et al.
Ann Hematol . 2021 Jan; 100(4):891-901. PMID: 33388858
Curcuminoids, polyphenol compounds in turmeric, possess several pharmacological properties including antioxidant, iron-chelating, and anti-inflammatory activities. Effects of curcuminoids in thalassemia patients have been explored in a limited number of studies...
6.
Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand
Chuncharunee S, Teawtrakul N, Siritanaratkul N, Chueamuangphan N
PLoS One . 2019 Mar; 14(3):e0214148. PMID: 30893381
Disease-related complications and management are different among patients with thalassemia. This study was aimed to review the prevalence, clinical risk factors for the complications and the management in patients with...
7.
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T
BMC Cancer . 2019 Mar; 19(1):184. PMID: 30819138
Background: Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematopoietic stem cell clonal diseases. Most patients with MPN are asymptomatic at diagnosis although some of them suffer...
8.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell...
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, et al.
Lancet Oncol . 2018 Oct; 19(11):1449-1458. PMID: 30348538
Background: In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were compared in...
9.
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy
Walewski J, Hellmann A, Siritanaratkul N, Ozsan G, Ozcan M, Chuncharunee S, et al.
Br J Haematol . 2018 Sep; 183(3):400-410. PMID: 30168134
Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1·8 ...
10.
Anemia and Neutropenia in Copper-Deficient Patients: A Report of Two Cases and Literature Review
Hantaweepant C, Chinthammitr Y, Siritanaratkul N
J Med Assoc Thai . 2018 Jun; 99(6):732-6. PMID: 29901325
Copper deficiency is an uncommon, but treatable cause of hematologic abnormalities. We present and describe two interesting cases in this report. The first case was a 37-year-old man with history...